The absolute bioavailability of<unk>  is about 95% in rat. In human, the mean steady state clearance (CLss/F) was 1.13 L/h across in 1 to 4 mg dose range. In the dose range, the mean half-life was 10.3 h. Urine excretion was negligible amount in elimination of<unk>  in rat and human. The plasma protein binding of the drug is over 99%. The average blood-to-plasma concentration ratio was 0.636. The unbound fraction of<unk>  in microsomal incubation medium was 0.479.<unk>  was primarily distributed to the liver with tissue-to-plasma concentration ratio as 5.59, and less to heart, lung, and fat. The tissue to plasma concentration ratios were ranged from about 0.25 to 4.0 for major tissues, in rat. Among six major membrane transporters recommended by the United States Food and Drug Administration,<unk>  interacts with OATP1B1, OAT3, and MDR1. In vitro,<unk>  was a substrate of rodent OATP1B2.<unk>  interacted with CYP1A2, 2C9 and 2C19. Distribution to liver of<unk>  was inhibited by atorvastatin, in rats.
Lobeglitazone
Exenatide
Miglitol
Liraglutide
Insulin degludec
Linagliptin
Glimepiride
Repaglinide